Geographic Atrophy

The designation is based off previously reported phase 3 data from the ongoing DRAGON trial.

Retina specialist Priya Vakharia, MD, reveals promising ANX007 trial results, showing potential to prevent vision loss in geographic atrophy.

Lineage Cell Therapeutics will be presenting data on the safety and tolerability of RG6501 (OpRegen) for the treatment of geographic atrophy, secondary to age-related macular degeneration during the upcoming Clinical Trials at the Summit 2025 meeting.

Kriya Therapeutics presented preclinical data on its gene therapy candidate for the treatment of geographic atrophy.

A recent analysis reveals a strong link between photoreceptor health and visual function in geographic atrophy, emphasizing the importance of EZ integrity.

A recent study reveals how geographic atrophy affects patients' vision and quality of life, highlighting their coping strategies and need for better resources.

Post hoc analysis of GATHER1 and GATHER2 showed that reduced EZ-RPE central subfield thickness is a strong predictor of greater future vision loss.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

Topline results from the Magnify phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Lukas Scheibler, PhD, and Graham Cooper join Tavo Biotherapeutics and chief research and development officer and chief financial officer.

Eyecyte-RPE is a suspension of human induced pluripotent stem cells derived from retinal pigment epithelial cells.

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency.

The first session of the 2025 COPHy meeting was titled "Big controversies in retina and beyond in 2025.”

The funding will help fund phase 1 and phase 2 proof-of-concept studies for lead candidates CTX203 and CTX114.

Investigators advised clinicians of the potential for dystrophies that mimic age-related macular degeneration and other atrophic macular pathologies to be incorrectly diagnosed, which can impact treatment.

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, wa first-in-class mitochondria-targeted investigational therapeutic.

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease.

This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.

The company also reported a positive outcome of an analysis of masked data from its ongoing MAGNIFY Phase 2 trial for zervimesine in adults with GA.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

The approval follows a refiling after the FDA issued a Complete Response Letter due to language on the amended label.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections

Among these eyes, 18.9% of eyes developed nAMD within 36 months.

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.